Opaleye Management Inc. 4 D Molecular Therapeutics, Inc. Transaction History

Opaleye Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.93 - $30.01 $34,053 - $48,826	1,627 Added 0.47%	345,750 $7.26 Million
Q1 2024 May 15, 2024	BUY	$17.03 - $35.87 $606,659 - $1.28 Million	35,623 Added 11.55%	344,123 $11 Million
Q3 2023 Nov 14, 2023	BUY	$12.64 - $19.76 $1.1 Million - $1.72 Million	86,800 Added 39.15%	308,500 $3.93 Million
Q2 2023 Aug 14, 2023	SELL	$15.16 - $23.26 $1.4 Million - $2.15 Million	-92,300 Reduced 29.39%	221,700 $4.01 Million
Q1 2023 May 12, 2023	SELL	$15.45 - $23.19 $247,200 - $371,040	-16,000 Reduced 4.85%	314,000 $5.4 Million
Q4 2022 Feb 10, 2023	SELL	$6.85 - $25.46 $141,795 - $527,022	-20,700 Reduced 5.9%	330,000 $7.33 Million
Q3 2022 Nov 14, 2022	BUY	$6.96 - $11.48 $178,872 - $295,036	25,700 Added 7.91%	350,700 $2.82 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $1.26 Million - $2.17 Million	96,000 Added 41.92%	325,000 $4.91 Million
Q4 2021 Feb 14, 2022	BUY	$19.56 - $32.94 $4.48 Million - $7.54 Million	229,000 New	229,000 $5.02 Million

144

57.7M

137K

111K

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $252M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.